Formulation Development
Andelyn Biosciences & Purespring Therapeutics Partner to Manufacture Novel Gene Therapies for Kidney Diseases
Andelyn Biosciences, Inc. has recently partnered with Purespring Therapeutics to accelerate the manufacture of their gene therapies for the treatment of chronic renal diseases that…
Aldena Therapeutics Selects PCI Pharma Services to Manufacture & Distribute Innovative Investigational Treatment for Dermatological Diseases
Aldena Therapeutics has chosen PCI Pharma Services (PCI) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for….
WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy
Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical…
Evonik Launches EUDRACAP Preclinic Functional Oral Capsule for Preclinical Trials
Evonik is launching a functional, ready-to-fill oral capsule designed for use in preclinical trials. EUDRACAP preclinic enteric is a very small size 9h (5.1 mm),…
Ovid Therapeutics & Ligand Pharmaceuticals Enter $30-Million Agreement
Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated recently announced Ligand has acquired a 13% portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of….
IMUNON Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. recently announced the first patient in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun…
Lisata Therapeutics Announces EMA Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
Lisata Therapeutics, Inc. recently announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug designation to LSTA1, the company’s lead…
Monte Rosa Therapeutics Announces Strategic Collaboration With Roche
Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEEN discovery engine with Roche’s strong expertise in delivering transformative therapies to patients….
Lumen Bioscience Awarded $16.2 Million in DoD Funding to Advance LMN-201 Through Late-Stage Trials
Lumen Bioscience recently announced it was awarded $16.2 million by the US Department of Defense to advance LMN-201 through late-stage trials. LMN-201 is an investigational,…
Elevar Therapeutics & Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement
Elevar Therapeutics, Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd. recently announced a global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with….
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase 2b Clinical Study
ABVC BioPharma, Inc. recently announced an update on the company's 8-week long ADHD Phase 2b clinical study taking place at the University of California San…
GRI Bio Announces Partnership With the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
GRI Bio, Inc. recently announced it has entered into a collaboration with the UK consortia, National Institute for Health and Care Research Respiratory Translational Research…
Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO
Quotient Sciences recently announce the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective October 16, 2023. Thierry succeeds Mark Egerton who….
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
Terns Pharmaceuticals, Inc. recently announced the US FDA’s clearance of its Investigational New Drug application and the design of the CARDINAL Trial, Terns’ global Phase…
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy Designation for Severe Sickle Cell Disease Treatment
Editas Medicine, Inc. recently announced the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene-editing medicine for the treatment of…
Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO
Daré to receive $1.8-million payment; eligible for additional potential milestone payments of up to $180 million and tiered double-digit royalties based on net sales…..
Silo Pharma’s Peptide Shows Positive Results Against Rheumatoid Arthritis
Silo Pharma, Inc. recently announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human…
WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects
This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….
Nemera Extends Manufacturing Capabilities in North America
With a newly acquired space in Vernon Hills, IL, Nemera opens a third location in the United States, in addition to the manufacturing facility in Buffalo Grove and Innovation center in Chicago….
eXmoor Completes Expansion Into Full-Service Cell & Gene Therapy CDMO Partner With Opening of GMP Facilities
eXmoor pharma recently launched its new Cell and Gene Therapy Centre GMP facility, to support the simultaneous production of multiple therapies for clinical trials. The…
